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Abstract
Neuroectodermal tumours are characterized by aberrant processing of disialogangliosides
concomitant with high expression of GD2 or GD3 on cell surfaces. Antibodies targeting
GD2 are already in clinical use for therapy of neuroblastoma, a solid tumour of early child-
hood. Here, we set out to identify peptides with high affinity to human disialoganglioside
GD2. To this end, we performed a combined in vivo and in vitro screen using a recombinant
phage displayed peptide library. We isolated a phage displaying the peptide sequence
WHWRLPS that specifically binds to the human disialoganglioside GD2. Binding specificity
was confirmed by mutational scanning and by comparative analyses using structurally
related disialogangliosides. In vivo, significant enrichment of phage binding to xenografts of
human neuroblastoma cells in mice was observed. Tumour-specific phage accumulation
could be blocked by intravenous coinjection of the corresponding peptide. Comparative
pharmacokinetic analyses revealed higher specific accumulation of 68Ga-labelled GD2-
binding peptide compared to 111In-labelled peptide in xenografts of human neuroblastoma.
In contrast to 124I-MIBG, which is currently evaluated as a neuroblastoma marker in PET/
CT, 68Ga-labelled GD2-specific peptide spared the thyroid but was enriched in the kidneys,
which could be partially blocked by infusion of amino acids.In summary, we here report on
a novel tumour-homing peptide that specifically binds to the disialoganglioside GD2, accu-
mulates in xenografts of neuroblastoma cells in mice and bears the potential for tumour
detection using PET/CT. Thus, this peptide may serve as a new scaffold for diagnosing
GD2-positive tumours of neuroectodermal origin.
Introduction
Neuroblastoma is the most common extracranial solid tumour of childhood. Its accounts for
more than 7% of malignancies in children younger than 15 years and approximately 15% of
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cancer related mortality in paediatric oncology patients. Neuroblastoma is a disease of the sym-
pathoadrenal lineage of the neural crest, and therefore tumours develop at various sites along
the sympathetic nervous system. Most primary tumours (65%) occur within the abdomen, and
the majority of these arise in the adrenal medulla. Other common sites of disease include neck,
chest, and pelvis [1, 2]. Few recurrent genetic events have been linked to neuroblastoma includ-
ing tumour-specific amplification of the MYCN oncogene or mutations in the genes coding for
anaplastic-lymphoma kinase (ALK) and the alpha thalassemia/mental retardation syndrome
X-linked (ATRX) gene [3, 4]. Recently, activation of telomerase by genomic rearrangements
has been identified as a hallmark of an aggressive subtype of neuroblastoma [5]. However, the
clinical problem in neuroblastoma is the lack of therapeutic options in relapsing disease [6],
which has been linked to significantly increasedmutational burden and RAS pathway activa-
tion [7, 8]. Thus, novel strategies for therapy and monitoring disease status of neuroblastoma
are eagerly awaited.
Interestingly, neuroblastoma tumour cells are characterized by expression of the disialogan-
glioside, GD2, on their surface. Generally speaking, disialogangliosides are part of a heteroge-
neous family of gangliosides. These glycosphingolipids consist of a ceramide lipid moiety and a
linked glycan chain of varying length and structure. The disialogangliosidesGD1b, GD2 and
GD3 are all composed of glucose linked to ceramide and a galactose, but differ in their terminal
moieties [9]. GD2 is found on cells of neuroectodermalorigin and its physiological distribution
in humans is limited to neurons and peripheral nerve fibres [10]. GD2 expression in tumours
is not restricted to neuroblastoma, but was also found on different tumour cells and tissues, for
example melanoma [11], osteosarcoma [12], uterine leiomyosarcoma [13], small cell lung can-
cer [14], Ewing sarcoma [15], retinoblastoma [16] and others [17]. GD2 is present on almost
all cell membranes of NB tumours regardless of stage, and is abundantly expressed with an esti-
mated 5–10 millionmolecules/cell [18]. It is suggested that shedding of GD2 and MYCN
amplification jointly characterize the most aggressive type of neuroblastomas [19]. Antibodies
directed against GD2 inhibit neuroblastoma cell attachment to extracellularmatrix compo-
nents like collagen, vitronectin, laminin and fibronectin [20]. Attachment to these matrix com-
ponents is mediated via an Arg-Gly-Asp (RGD) motif [21]. In GD2 expressing lung cancer
cells, the addition of a GD2 specific antibody caused growth reduction and apoptosis [22]. Ko
and co-workers demonstrated the invasive potential of GD2 positive lung cancer cells in con-
trast to GD2 negative cells [23], suggesting a role for GD2 also in metastatic processes. Taken
together, GD2 can contribute to cell growth, attachment to extracellularmatrix components
and enhance cell migration in different tumour entities.
Severalmurine, chimeric and humanized monoclonal antibodies (mAbs) have been devel-
oped to target GD2, ever since the prototypic mAb 3F8 was developed in 1985. Subsequently
murine mAbs, 14G2a, and the chimeric human variant ch14.18 were used in clinical trials for
the therapy of neuroblastoma [18]. Several clinical studies revealed that the combination of
mAb ch14.18, IL-2 and GM-CSF or variant GD2 antibody fused to IL-2 (mAb hu14.18-IL2)
showed increased efficiency to achieve long-term event-free survival of neuroblastoma patients
[24, 25]. Administration of GD2 specific antibodies is sufficient to induce cell death in neuro-
blastoma cell lines in vitro [26, 27]. Moreover, GD2 is also a valuable target for imaging pur-
pose, which was shown by radioactively labelledGD2 antibodies [28, 29]. Thus, GD2 has been
recognised as a target both for imaging and treatment of neuroblastoma [30, 31].
Phage display screening has been widely used for identification of specific oligopeptides rec-
ognizing different biological structures. It has been shown that peptide libraries displayed on
phages can be screened in vivo and in vitro for phages that home to a specific target. A number
of peptides capable of homing to tumour vasculature or structures on the surface of tumour
cells were isolated using phage display screenings [32–34]. Moreover, the therapeutic efficacy
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of these tumour-homing peptides coupled to cytotoxic drugs has been demonstrated in pre-
clinical models of cancer [35]. These peptides could also be used for imaging purposes [36].
Here, we applied phage display technology to identify peptides that specifically bind to the
human disialogangliosideGD2 and to characterise the tumour-homing ability and suitability
of these peptides for imaging human neuroblastoma cells using xenograft models.
Materials and Methods
Materials
Human gangliosides GD2, GD3, GD1b and GT1b were purchased fromHyTest (Turku, Fin-
land). The M13 phage library, the M13KE vector DNA, the enzymesAcc65I and EagI and the
phage-host bacteria Escherichia coli ER2738 were obtained fromNew England Biolabs (Frank-
furt/Main, Germany). Oligonucleotides were fromMWG Biotech (Ebersberg,Germany). Pep-
tide synthesis was performed by GL Biochem (Shanghai, China). Xylazine was acquired from
Bayer (Leverkusen,Germany). Ketamine was from Pfizer (Karlsruhe, Germany). Dulbecco´s
PBS (DPBS) were purchased from Invitrogen (Karlsruhe, Germany). Thiazolblue (MTT
reagent) was from Roth (Karlsruhe, Germany). All other chemicals were purchased from
Sigma-Aldrich (Taufkirchen, Germany).
Cell Culture
Human IMR32 neuroblastoma tumour cells expressing the disialogangliosideGD2 [27] were
purchased from DSMZ (Braunschweig, Germany) and maintained in DMEM (GlutaMax I,
Gibco, Karlsruhe, Germany) containing 10% fetal calf serum, 100 IE/ml penicillin, 100 μg/ml
streptomycin and 2,5 μg/ml Amphotericin B at 37°C in a humidified atmosphere containing
5% CO2.
Animals
NMRI nude mice (6–8 weeks old) were obtained from and kept at the central animal care facil-
ity of the University Hospital Essen, Germany. All animal experiments were carried out in
accordance with the guidelines of the German AnimalWelfare Act. Physical condition of the
animals was monitored daily and health and welfare were assessed using a score sheet defining
criteria for termination. Animal experiments were approved and supervisedby the North
Rhine-Westphalia State Environment Agency (Landesamt für Natur, Umwelt und Verbrau-
cherschutz NRW, record number 87–51.04.2010.A037).
IMR32 Neuroblastoma Tumour Model
Human IMR32 tumour cells were injected subcutaneously (s.c.) in the right and left femoral
region of anesthetizedNMRI nude mice (1×107 IMR32 cells in 50 μl DPBS and 150 μl Matrigel
(BD)). For PET imaging, IMR32 cells were injected s.c. in the neck fold. Imaging and all other
interventions were conducted on day 14 day after tumour cell inoculation.
Combined In Vivo/In Vitro Phage Display Screening
96-well microtiter plates (Greiner, Frickenhausen, Germany) were coated with 10 μg GD2 or
10 μg GD1b per well for one hour at room temperature. Wells were then washed 3 times with
DPBS/Tween20 (0.05%), blocked with BSA (1%)/DPBS/Tween20 (0.05%) for 1 hour at room
temperature, washed again and subsequently filledwith H2O. Plates were stored at 8°C until
use. For in vitro selection, 2 x 1011 plaque forming units (pfu) of the unselectedM13 Ph.D.-7
phage display peptide library or the phage pool of the subsequent selection rounds was
GD2-Binding Peptides
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incubated with DPBS/Tween20 (0.1%, 0.2%, 0,3% or 0,4%) in a GD1b coated well for 1 hour at
room temperature on a shaker. The phage solution was then transferred to a well containing
GD2 and incubated for 1 hour at room temperature. After washing 10 times with DPBS/
Tween20 (0.1%, 0.2%, 0,3% or 0,4%), bound phages were eluted by addition of E. coli ER2738
(OD600nm 0.4–0.5) for 30 minutes at 37°C. Phage amplification in 20 ml suspension containing
E. coli ER2738 (hereafter referred to as phage pool) and titer determination were performed
according to the manufacturer’s instructions with the modification that X-Gal was replaced by
S-Gal and ferric ammonium citrate (both obtained from Sigma, Taufkirchen, Germany). For in
vivo selection, 2 x 1011 pfu of the phage pool of the 3rd selection round were injected into the
tail vein of a mouse with a xenograft tumour induced by inoculation of IMR32 cells (2 x 107).
Anaesthetisedmice were perfusedwith DPBS 10 min after phage application. Tumours were
explanted, homogenized in LB-medium and the phages were eluted with 900 μl of an E. coli
ER2738 suspension at 37°C for 30 minutes in an incubator. Of this suspension, 10 μl were used
for the determination of the phage titer. The residual volume was used for phage amplification
in 20 ml E. coli ER2738 suspension according to the manufacturer’s instructions.
Phage Binding Assay
Wells were coated with GD3, GD2, GD1b, GT1b or BSA (10 μg/ well each). For competition
experiments, coated wells were pre-incubated with serial dilutions ranging from 10 μg to 100
pg of an 11-mer GD2-specific-peptide in DPBS for one hour at room temperature on a shaker
and the supernatant was removed. In total, 1 × 1011 pfu of the amplified phages were incubated
with DPBS/Tween20 (0.3%) for one hour at room temperature on a shaker. After washing with
10 volumes of DPBS/Tween20 (0.3%), bound phages were eluted by adding E. coli ER2738 and
phage titer determination was performed as described above. Additionally, an in vivo competi-
tion assay was performed in tumour-bearingmice. Therefore, 200 μg of the GD2-specific pep-
tide and 1×1011 pfu of the phage encoding the same peptide were co-injected intravenously in
three IMR32 tumour bearingmice per experiment. Tumours were subsequently harvested and
the phage titers were determined as described above.
Molecular Cloning of Phage Binding Sequence Motifs and Variants
Thereof
Modification of the phage binding motif was achieved by standard cloning procedures. The
corresponding oligonucleotides were annealed (cf. Table 1) and separately ligated into Acc65I /
EagI cleaved M13KE-phage DNA. Ligated DNA was transformed into E. coli ER2738 using the
TransformAid bacterial transformation kit (Fermentas, St. Leon-Rot, Germany) according to
the manufacturer’s instructions. Positive clones were identified using LB/S-Gal/IPTG-plates.
Following amplification, phage DNA was extracted using the E.Z.N.A. plasmid miniprep kit I
(peqLab, Erlangen, Germany) and inserts were verified by DNA sequencing.
Distribution of Phage In Vivo
Of the GD2-specific phage or a control phage (GHGRLPS), 1×1011 pfu were injected intrave-
nously in three IMR32 tumour bearingmice per phage after an i.p. application of the anaes-
thetics xylazine (16 mg/kg) and ketamine (100 mg/kg). After 10 minutes, the mice were
perfusedwith DPBS and brain, muscle, stomach, kidneys, heart, lung, spleen, liver and tumour
were explanted and weighed. Tissues were homogenized in LB-mediumusing an Ultra-Turrax
T25 homogenizer (IKA Labortechnik, Staufen, Germany). Phages were eluted by the addition
of E.coli ER2738 bacteria and the phage titers were determined as described above.
GD2-Binding Peptides
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Cell Proliferation Assay
Proliferation of the human neuroblastoma cell line IMR32 upon peptide addition was evalu-
ated usingMTT assays as described [37, 38]. Peptides were used at a concentration of 1 μg and
10 μg per well in a total volume of 200 μl per well. For each time point and each peptide con-
centration, experiments and controls were performed in quintuplicate.
Radiolabeling of DOTA Peptides
111In was solved in HCl and a pH 3 was adjusted. DOTA peptides (100 μg) were diluted in the
same volume of sodium acetate buffer (pH 5.0). Next, a 1:1 mixture (v/v) of the 111In /HCl
solution and the peptide solution was heated to 80°C for 10 minutes before applying it to a C18
reverse-phase cartridge (Strata™-X 33 μm Polymeric Reversed Phase, Phenomenex, Aschaffen-
burg, Germany). After washing twice with 5 ml water, elution of the 111In–labelled peptide was
achieved using ethanol abs. and volume was adjusted to 100 μl using isotonic NaCl solution.
Distribution of 111In -Labelled and 68Ga -labelled DOTA Peptides In Vivo
111In—labelledDOTA peptides (200–700 kBq) or 68Ga—labelledDOTA peptides (80–400
kBq) were injected intravenously into mice bearing IMR32-induced (2 x 107 cells s.c.) xeno-
grafts. Organs and blood of mice were collected between 5 min and 24 h after injection and
their radioactive content was quantified using a gamma counter (Automatic Gamma Counter
1480 Wizard TM 3”). The injected dose was calculated by weighing the syringe with and with-
out the tracer. Activity concentrations were corrected for radioactive decay. To evaluate the
effects of kidney protection, a mixture containing Gelofusine (80μg/ g bodyweight)/lysine
(400μg/ g weight)/arginine (400μg/ g weight) was injected i.v. 5 minutes before application of
the tracer. Here, organs and bloodwere collected 1 h after injection. To compare 68Ga -labelled
peptides with the clinically established tracer, one group of tumour bearingmice received 124I
-MIBG (100–200 kBq) by intravenous injection.
PET/MRT Imaging of 68Ga -Labelled DOTA Peptides
For PET imaging, ~ 7 MBq of 68Ga -labelledDOTA peptide were injected intravenously into
tumour bearingmice using kidney protection as described above. After 1 h, mice were
Table 1. DNA sequences of oligonucleotides used in this study.
Oligonucleotide Oligonucleotide sequence
mut1_for 5´-GTA CCT TTC TAT TCT CAC TCT GGT CAT TGG CGT CTT CCT TCT GGT GGA GGT TC-3´
mut1_rev 5´- GGC CGA ACC TCC ACC AGA AGG AAG ACG CCA ATG ACC AGA GTG AGA ATA GAA AG-3´
mut2_for 5´-GTA CCT TTC TAT TCT CAC TCT TGG CAT GGT CGT CTT CCT TCT GGT GGA GGT TC-3´
mut2_rev 5´- GGC CGA ACC TCC ACC AGA AGG AAG ACG ACC ATG CCA AGA GTG AGA ATA GAA AG-3´
mut3_for 5´-GTA CCT TTC TAT TCT CAC TCT TGG CAT TGG CGT CTT GGT TCT GGT GGA GGT TC-3´
mut3_rev 5´- GGC CGA ACC TCC ACC AGA ACC AAG ACG CCA ATG CCA AGA GTG AGA ATA GAA AG-3´
mut4_for 5´-GTA CCT TTC TAT TCT CAC TCT GGT CAT GGT CGT CTT CCT TCT GGT GGA GGT TC-3´
mut4_rev 5´- GGC CGA ACC TCC ACC AGA AGG AAG ACG ACC ATG ACC AGA GTG AGA ATA GAA AG-3´
mut5_for 5´-GTA CCT TTC TAT TCT CAC TCT GGT CAT GGT CGT CTT GGT TCT GGT GGA GGT TC-3´
mut5_rev 5´- GGC CGA ACC TCC ACC AGA ACC AAG ACG ACC ATG ACC AGA GTG AGA ATA GAA AG-3´
mut_for 5´-GCT CCT TTT GGA GCC TTT TT-3´
mut_rev 5´-ATT CCA CAG ACA GCC CTC AT-3´
-96gIII 5´-CCC TCA TAG TTA GCG TAA CG-3´
doi:10.1371/journal.pone.0163648.t001
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anesthetized by i.p. application of Fentanyl (1 μg/kg),Midazolam (0.1 mg/kg),Medetomidine
(10 μg/kg) and imaged using a PET/MRT scanner (Siemens Biograph mMR). PET images were
reconstructed by OSEM (ordered subset expectationmaximization) reconstructionwith 3 iter-
ations, 21 subsets using a zoom of 4 in a 344 matrix, and a Gaussian 2 mm FWHM post recon-
struction filter.
Statistical Analysis
Results are reported as arithmetic means ± standard error of mean (SEM). For analysing signif-
icance of the results, a t-test based on range [39] was used. In general, p< 0.05 was regarded as
significant.
Results
Combined In Vivo/In Vitro Phage Display Screening for Identification of
GD2-Binding Peptides
Specific phage ligands binding to immobilizedGD2 were identified by repetitive in vitro selec-
tion. After the third round of selection, the output was used for a subsequent in vivo selection
step. To this end, the phage pools were injected i.v. in mice bearing a tumour induced by s.c
implantation of IMR32 cells. Phages were then recovered from the tumour tissue and were
again tested for GD2 binding in vitro. One of the isolated phage clones (phage 7) displayed
high affinity to GD2 and a lower affinity to GD1b, while binding to gangliosides was less spe-
cific for other clones tested (Fig 1A). Sequencing revealed that phage 7 coded for a hepta-pep-
tide of sequenceWHWRLPS.
WHWRLPS-Phage Specifically Binds to the Disialoganglioside GD2
To characterize the specificity of theWHWRLPS-phage, we compared its binding properties to
different disialogangliosides (GD3, GD2, GD1b, and GT1b) as well as unspecific binding to
BSA and plastic. As an additional control for binding specificity, WHWRLPS-phage binding
characteristics were also compared to a non-binding control phage containing the hepta-pep-
tide HAIYPRH, which was designated phage 2. As expected, the control phage did not bind to
any of the disialogangliosidematrices tested. In contrast, WHWRLPS-phage specifically bound
to GD2 and to a lesser extent also to GD3, while binding to the other physiological gangliosides
was even less specific (Fig 1B). These results indicate that theWHWRLPS-phage specifically
binds to the disialogangliosideGD2.
Glycine Mutagenesis Scanning Reveals Specificity of WHWRLPS
Binding Site
In the next step, phage clones were produced in which single amino acids of the binding
sequence were changed to glycine (GHWRLPS,WHGRLPS,WHWRLGS,GHGRLPS or
GHGRLGS). As shown in Fig 1C, phages with an altered binding sequence showed impaired
binding to GD2 compared to theWHWRLPS-phage. These results confirm that the bulky
N-terminal tryptophans contribute to specific detection of the disialogangliosideGD2.
Inhibition of WHWRLPS Phage Binding to the Disialoganglioside GD2
by Competition with the Corresponding Peptide
Next, binding of theWHWRLPS-phage to GD2 was analysed in the presence of the cognate
peptide in a competition assay in vitro. We first analysed the impact of theWHWRLPS-peptide
GD2-Binding Peptides
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Fig 1. Identification of a GD2-specific binding peptide and binding characteristics of WHWRLPS-
phage in vitro. A) Individual phage clones (n = 12) derived from a phage display screen were tested for
binding to immobilized human GD1b, immobilized human GD2, or to BSA-coated surfaces. Phage clone 7
displayed the peptide sequence WHWRLPSand bound with high affinity to human GD2, and to a lesser extent,
to human GD1b. B) Binding affinity of WHWRLPS-phage (black bars) to GD3, GD2, GD1b, GT1, BSA or
GD2-Binding Peptides
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(1 μg or 10 μg/ml) on IMR32 cell viability. Maximum reduction of cell viability was observed
after 96 h and 10 μg/ml peptide when compared to the same amount of an unrelated control
peptide (Fig 2A). This suggests that binding of the GD2-specific peptide to IMR32 cells is
sufficient to reduce cell viability. As shown in Fig 2B, theWHWRLPS-peptide induced dose-
dependent reduction of phage binding with a maximum reduction of 82% in the presence of
10 μg peptide. Interestingly, a peptide concentration of as low as 100 pg/ml was sufficient to
polystyrol was tested and compared to control phage (white bars). “*” = p < 0.05 vs. GD2 binding of the
WHWRLPS-phage. C) Mutations in the displayed heptapeptide and resulting affinities to GD2. * p < 0.01 vs.
unmutated WHWRLPS-phage.
doi:10.1371/journal.pone.0163648.g001
Fig 2. The WHWRLPS-peptide inhibits IMR32 cell viability, binds specifically to human GD2 and displays tumour homing in vivo. A) Cell
viability of human neuroblastoma cells (IMR32) in the presence of the WHWRLPS peptide (1 μg [black] or 10 μg [dark grey]), a control peptide (1μg
[white] or 10 μg [light grey]) normalised to buffer control (PBS). “*” = p<0,05 vs. PBS control, “†” = p<0,05 vs. control peptide. B) Competition
experiments were performed in vitro to evaluated phage binding in the presence of soluble WHWRLPS-peptide. Shown are phage output titers using
different peptide concentrations for competition. “*” = p < 0.05 vs. 0 μg peptide. C) WHWRLPS-phage or control phage (GHGRLPS) were injected i.v.
mice bearing xenografts induced by s.c. injection of IMR32 cells. After 10 minutes of circulation the mice (n = 6 in each group) were sacrificed, the
tumours and the organs were explanted and the number of phage present was determined. Results are shown as fold change compared to control phage
(mean values ± SEM, “*” = p < 0.05 vs. control phage). D) WHWRLPS-phage and 200 μg WHWRLPS-peptide were coinjected i.v. in tumour-bearing
mice (n = 6). Mice were sacrificed 10 minutes later, the tumours and the organs were explanted and the number of phage present was determined.
Representative results of 3 independent experiments are shown (mean values ± SEM,”*” = p < 0.01 vs. control phage).
doi:10.1371/journal.pone.0163648.g002
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significantly reduce phage binding. These results demonstrate specificity of phage binding and
add an additional layer of evidence for specific binding of the cognate peptide to the disialogan-
gliosideGD2.
Analyses of Tumour-Homing by the WHWRLPS-Phage In Vivo
Biodistribution of theWHWRLPS-phage or a control phage harbouring a modified binding
motif (GHGRLPS) were analysed in vivo by comparing their tumour-homing ability. For this
purpose, eitherWHWRLPS-phage or control phage were injected i.v. into mice bearing
IMR32-induced xenografts. Significantly higher amounts of theWHWRLPS-phage could be
recovered from tumour tissue in comparison to control phage, while phage recovery from
other organs was lower than that of the control (Fig 2C). Notably, control phages did not accu-
mulate in tumour tissue.We next performed a competition assay in vivo by i.v. coinjection of
200 μgWHWRLPS-peptide and theWHWRLPS-phage in three mice bearing in IMR32-in-
duced xenografts. Phage recovery from tumour tissue was reduced by 84% in the presence of
the competing peptide compared to injection of phage only (Fig 2D). These results corroborate
to the findings obtained in vitro and furthermore confirm that homing of the peptide and
phage coding for theWHWRLPS occur at the same binding sites in the tumour.
Tumour-Homing of the 68Ga and 111In -Labelled DOTA-Peptide
WHWRLPS
111In—labelledWHWRLPS peptides (max. 700 kBq) were injected i.v. in mice bearing
IMR32-induced xenografts. Tissues and bloodwere collected at different time points ranging
between 5 min and 24 h and their activity concentration was determined. The maximum activ-
ity concentration in tumour tissue compared to bloodwas observedone hour after injection
(Fig 3A). As expected, unspecific accumulation of radioactivity in the kidneys was high, proba-
bly due to proximal tubular reabsorption of the peptide [40]. Calculation of the tumour/blood
ratio and the tumour/muscle ratio were determined to identify the optimal time point for sub-
sequent application in diagnostic settings (Fig 3B). One hour post injection the tumour/blood
ratio of radioactivity reached a maximum value of 1.6, while the tumour/muscle ratio was 8.3
at that time point. The tumour/muscle ratio reached a maximum value of 10 two hours after
injection. Comparison of the 111In -labelled and the 68Ga -labelled peptide one hour after injec-
tion revealed higher tumour-specific uptake for the 68Ga -labelled peptide (Fig 3C). Similarly,
the effects of 68Ga -labelledWHWRLPS-peptide and the diagnostic standard, 124I -MIBG,were
analysed in vivo using the same xenograft model one hour after tracer injection. As expected,
accumulation was highest in the thyroid for 124I -MIBG and in the kidney for the 68Ga labelled
peptide. Interestingly, the activity concentration in bloodwas higher for 124I -MIBGwhen
compared to the 68Ga labelled peptide, while accumulation in tumour tissue was comparable
for both tracers (Fig 3C).
PET Imaging of Tumour Using the 68Ga -Labelled DOTA-Peptide
WHWRLPS
Next, experiments using a diagnostic setting and PET imaging were conducted. For these stud-
ies, 68Ga-labelled peptides were used, which displayed higher uptake across all tissues in com-
parison to 111In–labelled peptides.We first analysed the effects of kidney protection by
injection of Gelofusine, lysine and arginine prior to injection of the tracer. Levels of radioactiv-
ity were unaltered in tumours, but the radioactive load in the kidneys was reduced. On the
other hand, kidney protection was accompanied by a higher accumulation of radioactivity in
GD2-Binding Peptides
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Fig 3. Tumour-homing of the 68Ga and 111In -labelled DOTA-peptide WHWRLPS compared to
124I-MIBG. A) The WHWRLPS-DOTA peptide was labelled with 111In and i.v. injected into mice (n = 3)
bearing xenografts induced by s.c. injection of IMR32 cells. Mice were sacrificed at indicated time-points,
tumours and organs were explanted and their activity concentration measured. Results are presented as
mean values ± SEM. B) Tumour/blood ratio (black bars) and tumour/muscle ratio (white bars) of 111In-
GD2-Binding Peptides
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the blood (Fig 4A), although this did not reach statistical significance.One hour after injection
of 68Ga-labelled peptides into mice bearing IMR32-induced xenografts, static pictures were
taken (Fig B–4D). Analyses of this picture series revealed tracer accumulation in tumour tissue
and also in the kidneys.
labelled WHWRLPS peptide using the data obtained in 3A, p.i. = post injection. C) The 68Ga- or 111In-labelled
WHWRLPS-DOTA peptides (black bars and grey bars, respectively) were injected i.v. in IMR32 tumour-
bearing mice (n = 3). As a control, 124I -MIBG (white bars) was administered to two mice. Mice were
sacrificed after one hour, the tumour and the organs were explanted and their activity concentration was
quantified. Results are presented as mean values ± SEM.
doi:10.1371/journal.pone.0163648.g003
Fig 4. PET imaging of tumour using the 68Ga -labelled DOTA-peptide WHWRLPS. A) For kidney protection, a mixture of Gelofundine, lysine
and arginine was i.v. injected in tumour-bearing mice prior to i.v. injection of the 68Ga-labelled WHWRLPS peptide. After one hour, mice were
sacrificed, tumours and organs were explanted and their radioactive content was quantified. All values were corrected for tissue weight and
radioactive decay. Results are presented as mean values ± SEM (black bars: no kidney protection, white bars: with kidney protection as described
above). B)-D) The 68Ga-labelled WHWRLPS peptide was i.v. injected in IMR32 tumour-bearing mice. After one hour, peptides were detected
using a PET/MRT scanner. B) PET image, C) MRI image and D) merge of B) and C).
doi:10.1371/journal.pone.0163648.g004
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Discussion
Expression of the disialogangliosideGD2 is observed in tumours of neuroectodermalorigin,
including neuroblastoma. As normal cells—with the exception of peripheral neurons- are
GD2-negative, this molecule holds great promise in serving as an exceptional target for diagno-
sis, imaging and therapy of GD2-positive cancers. Here, we aimed to identify peptides with
high specificity for GD2 and to evaluate their distribution in preclinical neuroblastoma models
in vitro and in vivo. For this purpose, we deployed a combined in vivo/in vitro phage-display
screening approach to ensure high target specificity and tumour homing ability using xeno-
grafts of human neuroblastoma in mice.We identified a phage motif with high affinity for
GD2 but lower affinity to the physiological gangliosides GD1b and GT1b. The same peptide
was found to bind to the melanoma specific ganglioside GD3 [41], albeit with intermediate
affinity. The binding of the phage to GD2 could be blocked by using the cognate peptide, thus
confirming specificity of phage binding to tumour-derived GD2. Modifying the phage binding
motif resulted in reduced affinity for GD2, especially when the N-terminal tryptophanmoieties
were converted to glycine. Proliferation of neuroblastoma tumour cells in vitro was decreased
in the presence of GD2-binding peptide. This is in line with findings using GD2 specificmono-
clonal antibodies, which have been reported by Doronin and co-workers to be also directly
cytotoxic [27]. The mode of cell death was not completely elucidated, but was specificallymedi-
ated by GD2-mAb binding to GD2 and the cytotoxic effect correlated with the GD2 content of
the cell [27]. Thus, in vitro results suggested that we obtained a phage and a peptidemotif spe-
cific for the disialogangliosideGD2.
In vivo, phages displaying the GD2-binding peptide accumulated in xenografts of human
neuroblastoma. This phage binding could be inhibited by co-injection of the cognate peptide
confirming the tumour homing ability of both, the phage and the peptide. Phage accumulation
was detected in the liver, the spleen and, to a lesser extent, in the lung. Most likely, this unspe-
cific uptake of WHWRLPS-phage can be attributed to the mononuclear phagocytic system
(MPS) in these organs [42]. This is corroborated by the fact that the control phages followed
the same distribution pattern [43] [44]. For pharmacokinetic analyses, we used 111In labelled
DOTA coupledWHWRLPS peptide in xenograft tumour bearingmice and found a strong
short-term enrichment in the tumour as well as in the kidneys. Comparison of 68Ga and 111In
DOTA-labelled peptides one hour after tracer injection revealed higher specific uptake of the
68Ga-DOTA labelled peptide in the tumour tissue. It remains to be elucidated, why the 111In-
labelled peptide showed a general lower uptake in the measured tissues. Comparison of the
clinical standard tracer for diagnosing neuroblastoma, 124I-labelledMIBG (metaiodobenzyl-
guanidine) [45], to the 68Ga-labelledDOTA coupledWHWRLPS peptide revealed comparable
patterns of tumour uptake. The high uptake of 124I-labelledMIBG in the thyroid may be caused
by free iodine due to de-iodination of the tracer, since the thyroid was not blocked in this
experiment. The 68Ga-labelled peptide showed substantially higher uptake in the kidneys com-
pared to 124I-MIBG (Fig 3C), which could be reduced by injection of a mixture of Gelofusine,
lysine and arginine. Reduced uptake in the kidney was accompanied by increased retention of
the 68Ga-labelled peptide in the blood. For simulation of a diagnostic setting, 68Ga -labelled
DOTA coupledWHWRLPS peptide was injected into mice bearing s.c. xenografts induced by
IMR32 neuroblastoma cells. Using a clinical PET/MRT scanner, the uptake pattern of the 68Ga
-labelledDOTA coupledWHWRLPS peptide was similar to the uptake pattern found in the
ex-vivo measurements. As intense uptake in the kidneys was the most prominent feature of the
PET images, kidney protection should be taken into consideration for optimizing the potential
diagnostic use of the labelled peptide and for reducing the radiation exposure. Amino acid
infusions have been recommended as nephroprotection for peptide receptor radiotherapy of
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neuroendocrine tumours (DOTA-TOC) [46–48]. In light of high kidney uptake despite amino
acid infusion, coupling of the peptide to PEG chains to change the excretion route of the pep-
tide should be evaluated, especially if a therapeutic use will be envisioned.
Taken together, we here describe identification, preclinical evaluation and pharmacody-
namics of a peptide, which specifically binds to the human disialogangliosideGD2. Tumour-
specific uptake of a 68Ga-labelled peptide was comparable to the clinically used 124I -MIBG at
one hour after tracer injection.We envisage coupling of this peptide to magnetic nanoparticles
or cytotoxic agents to further evaluate these in diagnostic and therapeutic settings, respectively,
in preclinical models of neuroblastoma.
Acknowledgments
The authors wish to thank Ivo Bendix and Ralf Herrmann (University Childrens Hospital
Essen) for technical support.
Author Contributions
Conceptualization:AS AE.
Data curation: SM JM.








Writing – original draft:AS JM.
Writing – review& editing:AS JM.
References
1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007; 369(9579):2106–20.
Epub 2007/06/26. doi: S0140-6736(07)60983-0 [pii] doi: 10.1016/S0140-6736(07)60983-0 PMID:
17586306.
2. Ora I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical
and basic research. Semin Cancer Biol. 2011; 21(4):217–28. Epub 2011/07/30. doi: S1044-579X(11)
00035-6 [pii] doi: 10.1016/j.semcancer.2011.07.002 PMID: 21798350.
3. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of
high-risk neuroblastoma. Nat Genet. 2013; 45(3):279–84. Epub 2013/01/22. doi: ng.2529 [pii] doi: 10.
1038/ng.2529 PMID: 23334666; PubMed Central PMCID: PMC3682833.
4. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK
provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975–8. Epub 2008/10/17. doi:
nature07397 [pii] doi: 10.1038/nature07397 PMID: 18923525; PubMed Central PMCID: PMC2587486.
5. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by
genomic rearrangements in high-risk neuroblastoma. Nature. 2015; 526(7575):700–4. Epub 2015/10/
16. doi: nature14980 [pii] doi: 10.1038/nature14980 PMID: 26466568.
GD2-Binding Peptides
PLOS ONE | DOI:10.1371/journal.pone.0163648 October 7, 2016 13 / 16
6. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of
patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;
56(4):578–83. Epub 2011/02/08. doi: 10.1002/pbc.22693 PMID: 21298742.
7. Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, et al. Mutational dynamics between
primary and relapse neuroblastomas. Nat Genet. 2015; 47(8):872–7. Epub 2015/06/30. doi: ng.3349
[pii] doi: 10.1038/ng.3349 PMID: 26121086.
8. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, et al. Relapsed neuroblastomas
show frequent RAS-MAPK pathway mutations. Nat Genet. 2015; 47(8):864–71. Epub 2015/06/30. doi:
ng.3333 [pii] doi: 10.1038/ng.3333 PMID: 26121087.
9. Daniotti JL, Iglesias-Bartolome R. Metabolic pathways and intracellular trafficking of gangliosides.
IUBMB Life. 2011; 63(7):513–20. Epub 2011/06/24. doi: 10.1002/iub.477 PMID: 21698755.
10. Czaplicki D, Horwacik I, Kowalczyk A, Wieczorek A, Bolek-Marzec K, Balwierz W, et al. New method
for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients. Acta Biochim Pol.
2009; 56(3):423–31. Epub 2009/09/03. doi: 20091812 [pii]. PMID: 19724779.
11. Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y, Furukawa K. Disialyl gangliosides enhance tumour
phenotypes with differential modalities. Glycoconj J. 2012; 29(8–9):579–84. Epub 2012/07/06. doi: 10.
1007/s10719-012-9423-0 PMID: 22763744.
12. Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, et al. Ganglioside GD2 as a therapeutic
target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014; 120(4):548–54.
Epub 2013/10/30. doi: 10.1002/cncr.28461 PMID: 24166473; PubMed Central PMCID: PMC3946333.
13. Ziebarth AJ, Felder MA, Harter J, Connor JP. Uterine leiomyosarcoma diffusely express disialoganglio-
side GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. Cancer
Immunol Immunother. 2012; 61(7):1149–53. Epub 2012/05/09. doi: 10.1007/s00262-012-1267-8
PMID: 22562378.
14. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, et al. Mechanisms for the
apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J
Biol Chem. 2005; 280(33):29828–36. Epub 2005/06/01. doi: M414041200 [pii] doi: 10.1074/jbc.
M414041200 PMID: 15923178.
15. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G
(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J
Cancer. 2012; 106(6):1123–33. Epub 2012/03/01. doi: bjc201257 [pii] doi: 10.1038/bjc.2012.57 PMID:
22374462; PubMed Central PMCID: PMC3304425.
16. Laurent VE, Otero LL, Vazquez V, Camarero S, Gabri MR, Labraga M, et al. Optimization of molecular
detection of GD2 synthase mRNA in retinoblastoma. Mol Med Report. 2010; 3(2):253–9. Epub 2011/
04/08. doi: 10.3892/mmr_00000248 PMID: 21472230.
17. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
FEBS Lett. 2014; 588(2):288–97. Epub 2013/12/04. doi: S0014-5793(13)00874-0 [pii] doi: 10.1016/j.
febslet.2013.11.030 PMID: 24295643.
18. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest.
2007; 25(1):67–77. Epub 2007/03/17. doi: 773165328 [pii] doi: 10.1080/07357900601130763 PMID:
17364560.
19. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumour gangliosides and pro-
gression of human neuroblastoma. Blood. 1990; 75(7):1564–7. Epub 1990/04/01. 2317562. PMID:
2317562
20. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved
in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell
Biol. 1986; 102(3):688–96. Epub 1986/03/01. doi: 10.1083/jcb.102.3.688 PMID: 3005335; PubMed
Central PMCID: PMC2114134.
21. Burns GF, Lucas CM, Krissansen GW, Werkmeister JA, Scanlon DB, Simpson RJ, et al. Synergism
between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to
matrix proteins by melanoma cells. J Cell Biol. 1988; 107(3):1225–30. Epub 1988/09/01. doi: 10.1083/
jcb.107.3.1225 PMID: 2458363; PubMed Central PMCID: PMC2115308.
22. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell
lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001;
61(10):4244–52. Epub 2001/05/19. PMID: 11358851.
23. Ko K, Furukawa K, Takahashi T, Urano T, Sanai Y, Nagino M, et al. Fundamental study of small inter-
fering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene.
2006; 25(52):6924–35. Epub 2006/07/25. 1209683 [pii] doi: 10.1038/sj.onc.1209683 PMID:
16862187.
GD2-Binding Peptides
PLOS ONE | DOI:10.1371/journal.pone.0163648 October 7, 2016 14 / 16
24. Bernstein ML. Targeted therapy in pediatric and adolescent oncology. Cancer. 2011; 117(10
Suppl):2268–74. Epub 2011/05/20. doi: 10.1002/cncr.26050 PMID: 21523745.
25. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res.
2012; 18(10):2740–53. Epub 2012/05/17. 18/10/2740 [pii] doi: 10.1158/1078-0432.CCR-11-1939
PMID: 22589483; PubMed Central PMCID: PMC3382042.
26. Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H. The GD2-specific 14G2a monoclonal
antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human
neuroblastoma cells. Cancer Lett. 2009; 281(2):171–82. Epub 2009/04/03. doi: S0304-3835(09)
00134-7 [pii] doi: 10.1016/j.canlet.2009.02.040 PMID: 19339105.
27. Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM, et al.
Ganglioside GD2 in reception and transduction of cell death signal in tumour cells. BMC Cancer. 2014;
14:295. Epub 2014/04/30. 1471-2407-14-295 [pii] doi: 10.1186/1471-2407-14-295 PMID: 24773917;
PubMed Central PMCID: PMC4021548.
28. Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, et al. Imaging cancer using PET—the
effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol.
2011; 38(1):29–38. Epub 2011/01/12. doi: S0969-8051(10)00327-6 [pii] doi: 10.1016/j.nucmedbio.
2010.07.003 PMID: 21220127; PubMed Central PMCID: PMC3032412.
29. Vavere AL, Butch ER, Dearling JL, Packard AB, Navid F, Shulkin BL, et al. 64Cu-p-NH2-Bn-DOTA-
hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med. 2012; 53
(11):1772–8. Epub 2012/10/16. doi: jnumed.112.104208 [pii] doi: 10.2967/jnumed.112.104208 PMID:
23064212.
30. Dobrenkov K, Cheung NK. GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol.
2014; 41(5):589–612. Epub 2014/12/03. doi: S0093-7754(14)00172-9 [pii] doi: 10.1053/j.seminoncol.
2014.07.003 PMID: 25440605; PubMed Central PMCID: PMC4254523.
31. Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert
Opin Ther Targets. 2015; 19(3):349–62. Epub 2015/01/22. doi: 10.1517/14728222.2014.986459
PMID: 25604432.
32. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for
destruction through a vascular address. Proc Natl Acad Sci U S A. 2002; 99(3):1527–31. Epub 2002/
02/07. doi: 10.1073/pnas.241655998 99/3/1527 [pii]. PMID: 11830668; PubMed Central PMCID:
PMC122224.
33. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-dis-
played peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A. 2002; 99
(4):2252–7. Epub 2002/02/21. doi: 10.1073/pnas.251687998 99/4/2252 [pii]. PMID: 11854520;
PubMed Central PMCID: PMC122351.
34. Gautam A, Kapoor P, Chaudhary K, Kumar R, Raghava GP. Tumour homing peptides as molecular
probes for cancer therapeutics, diagnostics and theranostics. Curr Med Chem. 2014; 21(21):2367–91.
Epub 2014/02/19. doi: CMC-EPUB-59220 [pii]. PMID: 24533809.
35. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumour vasculature. Curr Opin Oncol.
1998; 10(6):560–5. Epub 1998/11/18. PMID: 9818236.
36. Larimer BM, Thomas WD, Smith GP, Deutscher SL. Affinity maturation of an ERBB2-targeted SPECT
imaging peptide by in vivo phage display. Mol Imaging Biol. 2014; 16(4):449–58. Epub 2014/02/20.
doi: 10.1007/s11307-014-0724-5 PMID: 24550054.
37. Hatok J, Babusikova E, Matakova T, Mistuna D, Dobrota D, Racay P. In vitro assays for the evaluation
of drug resistance in tumour cells. Clin Exp Med. 2009; 9(1):1–7. Epub 2008/09/27. doi: 10.1007/
s10238-008-0011-3 PMID: 18818983.
38. Schwermer M, Lee S, Koster J, van Maerken T, Stephan H, Eggert A, et al. Sensitivity to cdk1-inhibi-
tion is modulated by p53 status in preclinical models of embryonal tumours. Oncotarget. 2015; 6
(17):15425–35. Epub 2015/06/02. doi: 3908 [pii]. PMID: 26029996; PubMed Central PMCID:
PMC4558161.
39. Moore PG. The two-sample t-test based on range. Biometrika. 1957; 44:482–9. doi: 10.2307/2332879
40. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled
peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for pre-
vention. J Nucl Med. 2010; 51(7):1049–58. Epub 2010/06/18. doi: jnumed.110.075101 [pii] doi: 10.
2967/jnumed.110.075101 PMID: 20554737.
41. Furukawa K, Hamamura K, Nakashima H, Furukawa K. Molecules in the signaling pathway activated
by gangliosides can be targets of therapeutics for malignant melanomas. Proteomics. 2008; 8
(16):3312–6. Epub 2008/08/12. doi: 10.1002/pmic.200800228 PMID: 18690647.
42. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. The mononuclear
phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull
GD2-Binding Peptides
PLOS ONE | DOI:10.1371/journal.pone.0163648 October 7, 2016 15 / 16
World Health Organ. 1972; 46(6):845–52. Epub 1972/01/01. doi: 10.1006/rwei.1999.0444 PMID:
4538544; PubMed Central PMCID: PMC2480884.
43. Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA. Uptake and processing of
modified bacteriophage M13 in mice: implications for phage display. Virology. 2002; 293(1):182–91.
Epub 2002/02/21. doi: 10.1006/viro.2001.1254 S0042682201912541 [pii]. PMID: 11853411.
44. Mueller J, Gaertner FC, Blechert B, Janssen KP, Essler M. Targeting of tumour blood vessels: a
phage-displayed tumour-homing peptide specifically binds to matrix metalloproteinase-2-processed
collagen IV and blocks angiogenesis in vivo. Mol Cancer Res. 2009; 7(7):1078–85. Epub 2009/07/09.
1541-7786.MCR-08-0538 [pii] doi: 10.1158/1541-7786.MCR-08-0538 PMID: 19584266.
45. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG
PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237–43. Epub 2009/07/21. doi: jnumed.108.060467
[pii] doi: 10.2967/jnumed.108.060467 PMID: 19617326.
46. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/
CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC,
68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37(10):2004–10. Epub 2010/07/03. doi: 10.
1007/s00259-010-1512-3 PMID: 20596866.
47. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during
peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging.
2010; 37(5):1018–31. Epub 2009/11/17. doi: 10.1007/s00259-009-1282-y PMID: 19915842.
48. Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine
tumours. Scand J Gastroenterol. 2015; 50(6):740–7. Epub 2015/05/12. 10.doi: 10.3109/00365521.
2015.1033454 PMID: 25959100; PubMed Central PMCID: PMC4487540.
GD2-Binding Peptides
PLOS ONE | DOI:10.1371/journal.pone.0163648 October 7, 2016 16 / 16
